-
公开(公告)号:US20060069107A1
公开(公告)日:2006-03-30
申请号:US10539574
申请日:2003-12-24
申请人: Shizuo Shiozaki , Junichi Shimada , Hiroshi Kase , Mayumi Shindo
发明人: Shizuo Shiozaki , Junichi Shimada , Hiroshi Kase , Mayumi Shindo
IPC分类号: A61K31/52
CPC分类号: A61K31/52 , A61K31/522
摘要: The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like.
摘要翻译: 本发明提供治疗诸如注意缺陷多动障碍的行为障碍的方法,其包括给予有效量的(E)-8-(3,4-二甲氧基苯乙烯基)-1,3-二乙基-7-甲基黄嘌呤或其药学上可接受的 其盐给有需要的患者等。
-
2.
公开(公告)号:US20090023755A1
公开(公告)日:2009-01-22
申请号:US12239955
申请日:2008-09-29
申请人: Shizuo Shiozaki , Junichi Shimada , Hiroshi Kase , Mayumi Shindo
发明人: Shizuo Shiozaki , Junichi Shimada , Hiroshi Kase , Mayumi Shindo
IPC分类号: A61K31/522 , A61P25/20 , A61P25/14
CPC分类号: A61K31/52 , A61K31/522
摘要: The present invention provides a method of treating behavioral disorders such as attention deficit hyperactivity disorder, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof and the like.
摘要翻译: 本发明提供治疗诸如注意缺陷多动障碍的行为障碍的方法,其包括给予有效量的(E)-8-(3,4-二甲氧基苯乙烯基)-1,3-二乙基-7-甲基黄嘌呤或其药学上可接受的 其盐给有需要的患者等。
-
公开(公告)号:US5670498A
公开(公告)日:1997-09-23
申请号:US527497
申请日:1995-09-13
申请人: Fumio Suzuki , Junichi Shimada , Nobuaki Koike , Hiroshi Kase , Joji Nakamura , Shizuo Shiozaki , Hiromi Nonaka
发明人: Fumio Suzuki , Junichi Shimada , Nobuaki Koike , Hiroshi Kase , Joji Nakamura , Shizuo Shiozaki , Hiromi Nonaka
IPC分类号: C07D473/06 , C07D473/12 , A61K31/52 , C07D473/10
CPC分类号: C07D473/06
摘要: Disclosed are xanthine derivatives represented by the following Formula (I): ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen or lower alkyl; Q.sup.1, Q.sup.2, and Q.sup.3 independently represent hydrogen, lower alkyl, lower alkoxy, or halogen; and X represents --COR.sup.4 (in which R.sup.4 represents hydrogen, hydroxy, lower alkyl, or lower alkoxy) or --SO.sub.2 R.sub.5 {in which R.sup.5 represents hydroxy, lower alkoxy, trifluoromethyl, ##STR2## in which R.sup.6 and R.sup.7 independently represent hydrogen, hydroxy-substituted or unsubstituted lower alkyl, aryl, or ##STR3## (in which m represents an integer of 1 to 3; and R.sup.8 and R.sup.9 independently represent hydrogen or lower alkyl), or ##STR4## (in which Y represents a single bond, oxygen, or N--R.sup.10 in which R.sup.10 represents hydrogen or lower alkyl; and n1 and n2 independently represent an integer of 1 to 3)}, and pharmaceutically acceptable salts thereof.
摘要翻译: 公开了由下式(I)表示的黄嘌呤衍生物:其中R 1,R 2和R 3独立地表示氢或低级烷基; Q1,Q2和Q3独立地表示氢,低级烷基,低级烷氧基或卤素; 或其中R 4表示氢,羟基,低级烷基或低级烷氧基)或-SO 2 R 5(其中R 5表示羟基,低级烷氧基,三氟甲基, 取代或未取代的低级烷基,芳基或者(其中m表示1〜3的整数; R 8和R 9分别表示氢或低级烷基),或者(其中Y表示单键,氧 ,或其中R 10表示氢或低级烷基的N-R 10,n1和n2独立地表示1〜3的整数)}及其药学上可接受的盐。
-
公开(公告)号:US5703085A
公开(公告)日:1997-12-30
申请号:US537770
申请日:1995-10-20
申请人: Fumio Suzuki , Nobuaki Koike , Junichi Shimada , Joji Nakamura , Shizuo Shiozaki , Shigeto Kitamura , Shunji Ichikawa , Hiroshi Kase , Hiromi Nonaka
发明人: Fumio Suzuki , Nobuaki Koike , Junichi Shimada , Joji Nakamura , Shizuo Shiozaki , Shigeto Kitamura , Shunji Ichikawa , Hiroshi Kase , Hiromi Nonaka
IPC分类号: C07D473/06 , A61K31/52 , C07D473/10 , C07D473/12
CPC分类号: C07D473/06
摘要: The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R.sup.4 represents lower alkyl, or substituted or unsubstituted aryl, R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R.sup.5 and R.sup.6 are combined together to represent --O--(CH.sub.2)p--O-- (p is an integer of 1 to 3), n represents 0, 1, or 2, and m represents 1 or 2. The compounds of the present invention have an adenosine A.sub.2 receptor antagonistic activity, and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A.sub.2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).
摘要翻译: PCT No.PCT / JP95 / 00267 Sec。 371 1995年10月20日第 102(e)1995年10月20日日期PCT提交1995年2月23日PCT公布。 公开号WO95 / 23148 日期:1995年8月31日本发明涉及由式(I)表示的新颖的黄嘌呤衍生物及其药学上可接受的盐:其中R1,R2和R3独立地表示氢,低级烷基,低级链烯基或 低级炔基,R 4表示低级烷基或取代或未取代的芳基,R 5和R 6独立地表示氢,低级烷基和低级烷氧基,或者R 5和R 6结合在一起代表-O-(CH 2)p O-(p是整数 1〜3),n表示0,1或2,m表示1或2.本发明化合物具有腺苷A2受体拮抗活性,可用于治疗或预防各种疾病 腺苷A2受体(例如帕金森病,老年性痴呆,抑郁症,哮喘和骨质疏松症)的过度高血症。
-
公开(公告)号:US20120232089A1
公开(公告)日:2012-09-13
申请号:US13447798
申请日:2012-04-16
申请人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
发明人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
IPC分类号: A61K31/519 , A61P25/22 , A61K31/522
CPC分类号: A61K45/06 , A61K31/00 , A61K31/519 , A61K31/522 , A61K2300/00
摘要: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
摘要翻译: 通过施用有效量的至少一种腺苷A2A受体拮抗剂来治疗焦虑症,例如恐慌症,广场恐怖症,强迫症,社交恐惧症,创伤后应激障碍,广泛性焦虑症,特异性恐惧症等。 任选地与除了腺苷A2A受体拮抗剂之外的抗焦虑药组合。
-
公开(公告)号:US08202869B2
公开(公告)日:2012-06-19
申请号:US10553250
申请日:2004-06-10
申请人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
发明人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
CPC分类号: A61K45/06 , A61K31/00 , A61K31/519 , A61K31/522 , A61K2300/00
摘要: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
摘要翻译: 通过施用有效量的至少一种腺苷A2A受体拮抗剂来治疗焦虑症,例如恐慌症,广场恐怖症,强迫症,社交恐惧症,创伤后应激障碍,广泛性焦虑症,特异性恐惧症等。 任选地与除了腺苷A2A受体拮抗剂之外的抗焦虑药组合。
-
公开(公告)号:US08592420B2
公开(公告)日:2013-11-26
申请号:US13447798
申请日:2012-04-16
申请人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
发明人: Hiroshi Kase , Naoki Seno , Shizuo Shiozaki , Minoru Kobayashi , Junya Kase
IPC分类号: A61K31/50 , A61K31/505 , A61K31/41
CPC分类号: A61K45/06 , A61K31/00 , A61K31/519 , A61K31/522 , A61K2300/00
摘要: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
摘要翻译: 通过施用有效量的至少一种腺苷A2A受体拮抗剂来治疗焦虑症,例如恐慌症,广场恐怖症,强迫症,社交恐惧症,创伤后应激障碍,广泛性焦虑症,特异性恐惧症等。 任选地与除了腺苷A2A受体拮抗剂之外的抗焦虑药组合。
-
公开(公告)号:US20060241102A1
公开(公告)日:2006-10-26
申请号:US10565239
申请日:2004-07-22
申请人: Hiroshi Kase , Minoru Kobayashi , Shizuo Shiozaki , Akihisa Mori , Naoki Seno
发明人: Hiroshi Kase , Minoru Kobayashi , Shizuo Shiozaki , Akihisa Mori , Naoki Seno
IPC分类号: A61K31/551 , A61K31/5415 , A61K31/496 , A61K31/522
CPC分类号: A61K31/522 , A61K31/137 , A61K31/138 , A61K31/16 , A61K31/335 , A61K31/343 , A61K31/36 , A61K31/38 , A61K31/381 , A61K31/435 , A61K31/4525 , A61K31/496 , A61K31/52 , A61K31/5375 , A61K31/55 , A61K31/553 , A61K45/06 , A61K2300/00
摘要: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
摘要翻译: 本发明提供了可用于治疗抑郁症等的药物组合物,其包含具有腺苷A 2A受体拮抗活性的化合物,例如(E)-8-(3,4 - 二甲氧基苯乙烯基)-1,3-二乙基-7-甲基-3,7-二氢-1H-嘌呤-2,6-二酮或其药学上可接受的盐和抗抑郁药(例如,三环抗抑郁药,四环抗抑郁药 ,选择性5-羟色胺再摄取抑制剂,选择性去甲肾上腺素再摄取抑制剂,多巴胺再摄取抑制剂,5-羟色胺去甲肾上腺素再摄取抑制剂,单胺氧化酶抑制剂,5-HT 2拮抗剂等),以及 喜欢。
-
公开(公告)号:US20120010225A1
公开(公告)日:2012-01-12
申请号:US13234355
申请日:2011-09-16
申请人: Hiroshi Kase , Minoru Kobayashi , Shizuo Shiozaki , Akihisa Mori , Naoki Seno
发明人: Hiroshi Kase , Minoru Kobayashi , Shizuo Shiozaki , Akihisa Mori , Naoki Seno
IPC分类号: A61K31/522 , A61P25/24
CPC分类号: A61K31/522 , A61K31/137 , A61K31/138 , A61K31/16 , A61K31/335 , A61K31/343 , A61K31/36 , A61K31/38 , A61K31/381 , A61K31/435 , A61K31/4525 , A61K31/496 , A61K31/52 , A61K31/5375 , A61K31/55 , A61K31/553 , A61K45/06 , A61K2300/00
摘要: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
摘要翻译: 本发明提供了可用于治疗抑郁症等的药物组合物,其包含具有腺苷A 2A受体拮抗活性的化合物,例如(E)-8-(3,4-二甲氧基苯乙烯基) 二乙基-7-甲基-3,7-二氢-1H-嘌呤-2,6-二酮或其药学上可接受的盐和抗抑郁药(例如,三环抗抑郁药,四环抗抑郁药,选择性5-羟色胺再摄取抑制剂, 选择性去甲肾上腺素再摄取抑制剂,多巴胺再摄取抑制剂,5-羟色胺去甲肾上腺素再摄取抑制剂,单胺氧化酶抑制剂,5-HT2拮抗剂等)等。
-
10.
公开(公告)号:US20070078148A1
公开(公告)日:2007-04-05
申请号:US10579829
申请日:2004-12-09
申请人: Hiroshi Kase , Yutaka Nakagawa , Shizuo Shiozaki , Minoru Kobayashi , Shinichiro Toki , Naoki Seno , Ken Ikeda
发明人: Hiroshi Kase , Yutaka Nakagawa , Shizuo Shiozaki , Minoru Kobayashi , Shinichiro Toki , Naoki Seno , Ken Ikeda
IPC分类号: A61K31/522
CPC分类号: C07D473/06 , A61K31/522
摘要: (wherein R1, R2 and R3 are the same or different, and represent a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl; R4 represents cycloalkyl, —(CH2)n—R5 or a group represented by the above formula (II); and X1 and X2 are the same or different, and represent an oxygen atom or a sulfur atom) The present invention provides, for example, agents for preventing and/or treating higher brain dysfunction comprising, as an active ingredient, a xanthine derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof.
摘要翻译: (其中R 1,R 2和R 3相同或不同,表示氢原子,低级烷基,低级烯基或低级 炔基; R 4表示环烷基, - (CH 2 CH 2)n -R 5或由下式表示的基团: 上述式(II); X 1和X 2相同或不同,表示氧原子或硫原子)本发明提供例如, 用于预防和/或治疗较高脑功能障碍的药物,其包含作为活性成分的由上式(I)表示的黄嘌呤衍生物或其药学上可接受的盐。
-
-
-
-
-
-
-
-
-